Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Dengue Vaccine Suffers Mixed Trial Results, But High Unmet Need Could Help It Forward

This article was originally published in The Pink Sheet Daily

Executive Summary

The efficacy seen in Sanofi’s Phase IIb dengue vaccine trial was modest. At least one dengue vaccine expert thinks the pharma would stand a better chance if it developed the vaccine as one dose instead of three.

You may also be interested in...



Sanofi Plans New Vietnam Plant Aimed At ASEAN Export Market

Sanofi plans to build its third manufacturing plant in Vietnam to expand exports into the Association of Southeast Asian Nations trading bloc and meet growing domestic demand. The company’s deep roots in the region via acquisitions give it an edge over other MNCs.

Vaccine Upstart Inviragen Aims to Capture Dengue Market

Six-year-old Inviragen may be the biotech of the future.

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel